Company Overview
Synexus Clinical Research Midco No 2 Limited is a Dissolved Private Limited Company.
Registered Address

12B Granta Park, Great Abington, Cambridge, CB21 6GQ
Credit Reports Available

These credit rating reports are available now:


Credit Analysts Report
Get Report >>

Standard Credit Report
Get Report >>

Basic Credit Report
Get Report >>

24/7 credit rating data feed - no UK company credit reports are updated faster

Companies House Data
Company NameSYNEXUS CLINICAL RESEARCH MIDCO NO 2 LIMITED
Company Number07260768
Registered Office Address12b Granta Park
 CB21 6GQ
Company CategoryPrivate Limited Company
Company StatusDissolved
Country of OriginUnited Kingdom
Incorporation Date21/05/2010
Accounting Reference Date Day31
Accounting Reference Date Month12
Accounts Next Due Date30/09/2021
Accounts Last Made Up Date31/12/2019
Accounts Account CategoryFULL
Returns Next Due Date18/06/2017
Returns Last Made Up Date21/05/2016
Previous Company NameChanged Date
SYNEXUS CLINICAL RESEARCH TOPCO LIMITED16 Jun 2015
DE FACTO 1772 LIMITED23 Nov 2010
Directors & Members
Show Resigned
Richard Harris - Director
(British, 47 years old, born December 1979)
Appointed 29 December 2021
 Active
Julia James - Director
(British, 52 years old, born July 1974)
Appointed 31 May 2016
 Active
Secretaries
Show Resigned
Other Company Directorships
Richard Harris
CLINICAL TECHNOLOGY CENTRE (INTERNATIONAL) LIMITED
EVIDERA LTD
MEDICI GLOBAL LTD.
PPD GLOBAL LTD
PPD INTERNATIONAL HOLDINGS (UK) LTD.
PPD INTERNATIONAL INVESTMENTS LIMITED
PPD UK HOLDINGS LIMITED
SAAMA TECHNOLOGIES UK LIMITED
STOWMARKET GOLF CLUB LIMITED
SYNEXUS CLINICAL RESEARCH ACQUISITIONS LIMITED
SYNEXUS CLINICAL RESEARCH FINANCE LIMITED
SYNEXUS CLINICAL RESEARCH LIMITED
SYNEXUS CLINICAL RESEARCH MIDCO NO 1 LIMITED
SYNEXUS CLINICAL RESEARCH MIDCO NO 3 LIMITED
SYNEXUS CLINICAL RESEARCH MIDCO NO 4 LIMITED
SYNEXUS CLINICAL RESEARCH TOPCO LIMITED
SYNEXUS LIMITED
Julia James
CLINICAL TECHNOLOGY CENTRE (INTERNATIONAL) LIMITED
DATA ANALYSIS AND RESEARCH (DAR) LIMITED
ERESEARCHTECHNOLOGY LIMITED
EVIDERA ACCESS CONSULTING LTD
EVIDERA HOLDINGS LTD
EVIDERA LTD
MEDICI GLOBAL LTD.
PANOPLY HEALTH LIMITED
PPD GLOBAL LTD
PPD INTERNATIONAL HOLDINGS (UK) LTD.
PPD INTERNATIONAL INVESTMENTS LIMITED
PPD UK HOLDINGS LIMITED
SYNEXUS (TRUSTEES) LIMITED
SYNEXUS CLINICAL RESEARCH ACQUISITIONS LIMITED
SYNEXUS CLINICAL RESEARCH FINANCE LIMITED
SYNEXUS CLINICAL RESEARCH LIMITED
SYNEXUS CLINICAL RESEARCH MIDCO NO 1 LIMITED
SYNEXUS CLINICAL RESEARCH MIDCO NO 3 LIMITED
SYNEXUS CLINICAL RESEARCH MIDCO NO 4 LIMITED
SYNEXUS CLINICAL RESEARCH TOPCO LIMITED
SYNEXUS LIMITED
Balance Sheet Unlock full report
Accounts Date 31-Dec-2019 31-Dec-2011 31-Dec-2010
Balance Sheet
Fixed Assets 61,188,000 61,188,000 64,933,000
Current Assets 5,987,000 5,987,000 9,692,000
Creditors Due Within One Year 12,460,000 12,460,000 22,743,000
Working Cap -6,473,000 -6,473,000 -13,051,000
Total Assets Less Current Liabilities 54,715,000 54,715,000 51,882,000
Long-term Liabilities 71,302,000 71,302,000 51,773,000
Net Assets -16,587,000 -16,587,000 109,000
Share Capital & Reserves
Share Cap 900,000 900,000 900,000
Profit & Loss Reserves -17,487,000 -17,487,000 -791,000
Other Reserves 0 0 0
Shareholders Funds -16,587,000 -16,587,000 109,000
Common Size Financial Analysis Unlock full report
Accounts Date 31-Dec-2019 31-Dec-2011 31-Dec-2010
Tangible Fixed Assets - - -
Fixed Assets 91.1% 91.1% 87.0%
Stocks Inventory 0.0% 0.0% 0.0%
Debtors 7.9% 7.9% 9.3%
Cash Bank In Hand 1.0% 1.0% 3.7%
Current Assets 8.9% 8.9% 13.0%
Creditors Due Within One Year 18.5% 18.5% 30.5%
Net Current Assets Liabilities -9.6% -9.6% -17.5%
Creditors Due After One Year 106.1% 106.1% 69.3%
Accruals Deferred Income - - -
Provisions For Liabilities Charges - - -
Net Assets Liabilities Including Pension Asset Liability -24.7% -24.7% 0.1%
Called Up Share Capital 1.3% 1.3% 1.2%
Share Capital Allotted Called Up Paid 1.3% 1.3% 1.2%
Profit Loss Account Reserve -26.0% -26.0% -1.1%
Shareholder Funds -24.7% -24.7% 0.1%
Capital Employed - - -
Total Assets Less Current Liabilities 81.5% 81.5% 69.5%
Financial Ratio Analysis Unlock full report
Accounts Date 31-Dec-2019 31-Dec-2011 31-Dec-2010
Liquidity Ratio 0.5 0.5 0.4
Solvency Ratio 0.8 0.8 1.0
Reserves to Assets -0.3 -0.3 0.0
Secured Creditors Unlock full report
Mortgages Charges 3
Mortgages Outstanding 0
Mortgages Part Satisfied 0
Mortgages Satisfied 3
Assets and Debt Analysis Unlock full report
Accounts Date 31-Dec-2019 31-Dec-2011 31-Dec-2010
Assets 67,175,000 67,175,000 74,625,000
Debt 83,762,000 83,762,000 74,516,000
Net Assets/Debt -16,587,000 -16,587,000 109,000
Public Record Information Unlock full report
Exact Court Judgements
Period of Months Last 12m 13-24m 25-36m 37-48m 49-60m 61-72m
Number of Exact CCJS X Y Y X X Y
Value of Exact CCJS YXY YK S S X KX
Supplier Credit Limits Unlock full report
Date Sector Notified Amount Terms
XK-SXY XKXYXK SXSKXYXK £X,000 XS XYSKS
SK-SYY SKXYXKYKKY KSXX KKXXYXS £YY,000 YS XYSKS SK YXXSXS
YK-SXY XKXYXYYK SXSXYXK £SX,000 XS XYSKS
Payment Records Unlock full report
Payment Records from it's suppliers' company ledger show how a company is paying its suppliers

Payment Analysis

Total Invoices Paid Before
30 days due		 Paid After
30 days due		 Owing Before
30 days due		 Owing after
30 days due
XYX SX K YX X
Company Valuation Analysis Unlock full report

Going Concern Valuation

The going concern valuations value the company on the basis that it continues to trade without the threat of liquidation for the foreseeable future. These valuations are primarily profit and cashflow based.

Valuations Valuation Measures
Estimated High Value £XSI,000 Retained Profit £YX,000
Estimated Mid Value £YY,000 EBIT £SY,000
Estimated Low Value £X,000 EBITDA £SSX,000

Liquidation Valuation

The liquidaton valuation values the company as if it were to cease trading and assets were subject to rapid disposal to cover liabilities. This valuation is primarily asset based.

Valuations Valuation Measures
Estimated High Value £XY,000 Total Assets £XIX,000
Estimated Mid Value £Y,000 Net Assets £YX,000
Estimated Low Value £S,000 Tangible Equity £SX,000

The above valuations are based on our own algorithms and take no account of many factors that can influence actual valuations realized and should not therefore be assumed to be accurate.
Credit Status Checklist Unlock full report
Business Growth Please purchase a report to see true comments
EBITDA Purchase a report to see true comments
Dividends Please purchase a report to see true comments about this company
Retained Profits Retained Profits for this company
Debt Interest Debt Interest for this company
Cash Flow Cash Flow for this company
CCJs CCJs for this company
Age of Company Age of Company for this company
Solvency Solvency for this company
Secured Creditors Secured Creditors for this company
Ownership Ownership for this company


First Report Score: (0-10) X
Financial Status Guide:
10 Very Strong
9 Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical

Risk Score Trend

Risk Rating Unlock full report

This is the credit risk assessment used by one of the top UK credit reference agencies.

Risk Score (1-100) X
Risk Band Description XXMXMXMX SISX
Risk Assessment Meeting of Creditors
Credit Rating XSKX
Altman Z Score Credit Risk Rating Unlock full report

There have been many bankruptcy predictors developed, however none has been so thoroughly tested and broadly accepted as the Altman Z-Score.

Z Score X
Risk Band XY
Risk Band Description The Z Score is not used for small companies where full accounts are not filed because profit and loss account items are required to calculate the score.

Z Score Bands

1 Low Risk 3.00 and above
2 Caution 2.63 - 2.99
3 Risk of Failure within 2 years 1.24 - 2.62
4 High Probability Failure Below 1.24
Other Business around CB21 6GQ
CLINICAL TECHNOLOGY CENTRE (INTERNATIONAL) LIMITED
GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CAMBRIDGESHIRE, CB21 6GQ
PPD CT INVESTMENTS LLP
GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CAMBRIDGESHIRE, CB21 6GQ
PPD INTERNATIONAL INVESTMENTS LIMITED
PPD GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CAMBRIDGESHIRE, CB21 6GQ
GABBAY LIMITED
Granta Park, Great Abington, Cambridge, Cambridgeshire, CB21 6GQ
PPD GLOBAL LTD
GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CAMBRIDGESHIRE, CB21 6GQ
PPD UK HOLDINGS LIMITED
GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CAMBRIDGESHIRE, CB21 6GQ
CHELMSFORD CLINICAL TRIALS UNIT LIMITED
Granta Park, Great Abington, Cambridge, Cambridgeshire, CB21 6GQ
WILDCAT ACQUISITION HOLDINGS (UK) LIMITED
GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CB21 6GQ
CLINICAL SCIENCE RESEARCH INTERNATIONAL LIMITED
Granta Park, Great Abington, Cambridge, Cambridgeshire, CB21 6GQ
PANOPLY HEALTH LIMITED
C/O Ppd Global Limited Granta Park, Great Abington, Cambridge, CB21 6GQ
Document Filings
Final Gazette dissolved via voluntary strike-off
First Gazette notice for voluntary strike-off
Application to strike the company off the register
Appointment of Mr Richard Stuart Harris as a director on 29 December 2021
Termination of appointment of Brainard Judd Hartman as a director on 8 December 2021
Change of details for Synexus Clinical Research Midco No 1 Limited as a person with significant control on 1 September 2021
Registered office address changed from Sandringham House Ackhurst Business Park, Foxhole Road Chorley Lancashire PR7 1NY to 12B Granta Park Great Abington, Cambridge CB21 6GQ on 1 December 2021
First Gazette notice for compulsory strike-off
Confirmation statement made on 21 May 2021 with no updates
Register inspection address has been changed to Eversheds Sutherland (International) Llp 70 Great Bridgewater Street Manchester M1 5ES
Confirmation statement made on 21 May 2020 with no updates
Termination of appointment of Christopher David Neild as a director on 13 March 2020
Confirmation statement made on 21 May 2019 with no updates
Confirmation statement made on 21 May 2018 with no updates
Confirmation statement made on 21 May 2017 with updates
Statement of capital on 31 August 2016
Statement by Directors
Solvency Statement dated 31/08/16
Resolutions
Annual return made up to 21 May 2016 with full list of shareholders
Termination of appointment of Paul Michael Chambers as a director on 31 May 2016
Terms and Conditions Cancellations Contact Us

In using this service you agree to the Terms and Conditions

© 2026 Check Free